Role of von Willebrand factor in immune tolerance induction

Blood Coagulation and Fibrinolysis

Volumn 16, Issue SUPPL. 1, 2005, Pages

  Ettingshausen, Carmen Escuriola ^a   Kreuz, Wolfhart ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Factor VIII concentrates; Hemophilia A; Immune tolerance induction; Inhibitors; Plasma derived; Recombinant

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; HELIXATE FS; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

BLEEDING; BLEEDING TENDENCY; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

EID: 19944390186     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000167660.30886.e9     Document Type: Review

References (22)

1. Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88(suppl 9):17-20.
2. Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: Results of an international clinical investigation. Thromb Haemost 2005; 93:457-467.
3. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339:594-598.
4. Addiego J, Kaser C, Abildgaard C, Hilgartner M, Lusher J, Glader B, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342:462-464.
5. Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339:1550.
6. De Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Biasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma-derived concentrates. Thromb Haemost 1994; 71:544-547.
7. Gruppo R, Bray GL, Schroth P, Perry M, Gomperts ED. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): a 6.5 year update. The Recombinate PUP Study Group [abstract]. Thromb Haemost 1997; 162(suppl):PD-663.
8. Lusher JM, Shapiro A, Gruppo R, Bedrosian CL, Nguyen K, and the ReFacto PUP Study Group. Safety and efficacy in previously untreated patients (PUPs) treated exclusively with b-domain deleted factor VIII (BDD rFVIII)[abstract]. Thromb Haemost 2001; (suppl):2558.
9. Kreuz W, Ehrenforth S, Funk M, Auerswald G, Mentzer D, Joseph-Steiner J, et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1:24-32.
10. Brackmann HH, Gormsen J. Massive factor VIII infusion in haemophiliac with factor-VIII inhibitor, high responder [letter]. Lancet 1977; 29:933.
11. Mauser-Bunschoten EP, Nieuwenhuis KH, Rosendaal G, van den Berg M. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86:983-988.
12. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: Current Practice Implications. The ISTH Factor VIII/IX Subcommittee Members. Vox Sang 1999; 77:28-30.
13. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982-95. Haemophilia 1999; 5:32-39.
14. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999; 77:49-54.
15. Kreuz W, Escuriola Ettingshausen C, Auerswald G, Heidemann P, Kemkes-Matthes B, Schneppenheim R, et al. Immune tolerance induction (ITI) in haemophilia A patients with inhibitors: the choice of concentrate affecting success. Haematologica 2001; 86(suppl 4):16-20.
16. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88(suppl 9):21-25.
17. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Hemophilia 1996; 2:95-99.
18. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76:749-754.
19. Gensana M, Altisent C, Aznar JA, Casana P, Hernandez F, Jorquera JI, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7:369-374.
20. Astermark J, Voorberg J, Lenk H, DiMichele D, Shapiro A, Tjönnfjord G, et al. Impact of the inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9:567-572.
21. Berntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 2001; 7:109-113.
22. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330:38-47.